Cytotoxic biotransformed products from cinobufagin by Mucor spinosus and Aspergillus Niger

Steroids

Volumn 71, Issue 5, 2006, Pages 392-402

  He, Xiangjiu ^a,b   Tang, Jinshan ^c   Qiao, Aimin ^c   Wang, Guanghui ^c   Jiang, Miaomiao ^c   Liu, Rui Hai ^b   Yao, Xinsheng ^a,c  

^a JINAN UNIVERSITY   (China)

^b Department of Obstetrics Gynecology   (United States)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anticancer activities; Aspergillus niger; Cinobufagin; Mucor spinosus; Steroid microbial conversion

Indexed keywords

12BETA HYDROXYLBUFALIN; 12BETA HYDROXYLCINOBUFAGIN; 12BETA HYDROXYLDESACETYLCINOBUFAGIN; 1BETA HYDROXYLCINOBUFAGIN; 1BETA,12BETA HYDROXYLCINOBUFAGIN; 3 EPI 12BETA HYDROXYLCINOBUFAGIN; 3 OXOCINOBUFAGIN; 3 OXODESACETYLCINOBUFAGIN; 5BETA HYDROXYLCINOBUFAGIN; 7BETA HYDROXYLBUFALIN; BUFALIN; CINOBUFAGIN; DESACETYLCINOBUFAGIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPERGILLUS NIGER; BIOTRANSFORMATION; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEGRADATION; FAST ATOM BOMBARDMENT MASS SPECTROMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MUCOR; MUCOR SPINOSUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; ASPERGILLUS NIGER; BIOTRANSFORMATION; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; HUMANS; LEUKEMIA; MOLECULAR CONFORMATION; MUCOR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

ASPERGILLUS NIGER; FUNGI; MUCOR; MUCOR SPINOSUS;

EID: 33646412042     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2005.12.003     Document Type: Article

References (29)

1. Steyn P.S., and Heerden F.R. Bufadienolides of plant and animal origin. Nat Prod Rep 15 (1998) 397-413
2. Ogasawara M., Matsubara T., and Suzuki H. Screening of natural compounds for inhibitory activity on colon cancer cell migration. Biol Pharm Bull 24 6 (2001) 720-723
3. Zhang L., Nakaya K., Yoshida T., and Kuroiwa Y. Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 178 2 (1991) 686-693
4. Zhang L.S., Nakaya K., Yoshida T., and Kuroiwa Y. Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 52 (1992) 4634-4641
5. Hashimoto S., Jing Y., Kawazoe N., Masuda Y., Nakajo S., Yoshida T., et al. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the Cytotoxicity of anticancer drugs. Leuk Res 21 (1997) 875-883
6. Su Y.H., Yin X.C., Xie J.M., Gao B., and Ling C.Q. Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines. Dier Junyi Daxue Xuebao 24 4 (2003) 393-395
7. Kamano Y., Yamashita A., Nogawa T., Morita H., Takeya K., Itokawa H., et al. QSAR evaluation of the Chan'Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5. J Med Chem 45 25 (2002) 5440-5447
8. Zhao J.B., Cui Q., Zhang X., Wang W.L., and Jiang Y.P. Experimental study on anticancer action of cinobufagin in vitro. Disi Junyi Daxue Xuebao 22 16 (2001) 1504-1507
9. Yeh J.Y., Huang W.J., Kan S.F., and Wang P.S. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54 2 (2003) 112-124
10. Wang R., Wan K., Gao Z.M., and Wang S.L. Effect of cinobufagin inhibiting proliferation of NIH/3T3 cells on prevention and cure of organ fibrosis. Zhongguo Linchuang Kangfu 8 5 (2004) 918-919
11. Hong Z., Chan K., and Yeung H.W. Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation Liu-Shen-Wan by liquid chromatography. J Pharm Pharmacol 44 (1992) 1023-1026
12. Rosazza JPN, and Duffel M.W. Metabolic transformation of alkaloids. In: Brossi X. (Ed). Alkaloids: chemistry and pharmacology vol. 27 (1986), Academic Press, New York 391-392
13. Fernandes P., Cruz A., Angelova B., Pinheiro H.M., and Cabral J.M.S. Microbial conversion of steroid compounds: recent developments. Enzyme Microb Technol 32 (2003) 688-705
14. Zhang W., Ye M., Qu G.Q., Wu W.Y., Chen Y.J., and Guo D.A. Microbial hydroxylation of cinobufagin by Mucor spinosus. J Asian Nat Prod Res 7 3 (2005) 225-229
15. Ye M., Qu G.Q., Guo H.Z., and Guo D.A. Specific 12-hydroxylation of cinobufagin by filamentous fungi. Appl Environ Microbiol 70 6 (2004) 3521-3527
16. Zhan J.X., Liu W.H., Guo H.Z., Zhang Y.X., and Guo D.A. Selective dehydrogenation of resibufogenin and cinobufagin at 3-OH by Pseudomonas aeruginosa. Enzyme Microb Technol 33 1 (2003) 29-32
17. Ye M., Ning L.L., Zhan J.X., Guo H.Z., and Guo D.A. Biotransformation of cinobufagin by cell suspension cultures of Catharanthus roseus and Platycodon grandiflorum. J Mol Catal B: Enzym 22 1-2 (2003) 89-95
18. Ye M., Dai J.G., Guo H.Z., Cui Y.J., and Guo D.A. Glucosylation of cinobufagin by cultured suspension cells of Catharanthus roseus. Tetrahedron Lett 43 47 (2002) 8535-8538
19. Toma S., Morishita S., Kuronuma K., Mishima Y., Hirai Y., and Kawakami M. Metabolism and pharmacokinetics of cinobufagin. Xenobiotica 17 10 (1987) 1195-1202
20. Toma S., Hirai Y., Sugimoto C., Shoji M., Oguni Y., Morishita S., et al. Metabolic fate of bufalin and cinobufagin. Yakugaku Zasshi 111 11 (1991) 687-694
21. Zhang L.S., Yoshida T., Aoki K., and Kuroiwa Y. Metabolism of cinobufagin in rat liver microsomes. Identification of epimerized and deacetylated metabolites by liquid chromatography/mass spectrometry. Drug Metab Dispos 19 5 (1991) 917-919
22. Zhang L.S., Aoki K., Yoshida T., and Kuroiwa Y. Deacetylation of cinobufagin by rat liver. Drug Metab Dispos 20 1 (1992) 52-55
23. Yang X.W., Xing Z.T., Cui J.R., Fan Y.L., Zhao R., and Li X.G. Studies on metabolism of cinobufagin and cinobufotalin by human intestinal bacteria. Beijing Daxue Xuebao, Yixueban 33 3 (2001) 199-204
24. Song H.T., Guo T., Bi K.S., Wang H.R., and Zhang R.H. Determination of resibufogenin and cinobufagin in heart-protecting musk pill by HPLC. Biomed Chromatogr 14 2 (2000) 130-132
25. Mizutani Y., Bonavida B., Koishihara Y., Akamatsu K., Ohsugi Y., and Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedi-chloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55 (1995) 590-596
26. Carmichel J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47 (1987) 936-942
27. Furuya T., Kawaguchi K., and Hirotani M. Biotransfornationof digitoxigenin by cell suspension cultures of Strophanthus grantus. Phytochemistry 27 (1988) 2129-2133
28. Ye M., Qu G.Q., Guo H.Z., and Guo D.A. Novel cytotoxic bufadienolides derived from bufalin by microbial hydroxylation and their structure-activity relationships. J Steroid Biochem Mol Biol 9 (2004) 87-98
29. Kamano Y., Kotake A., Hashima H., Inoue M., Morita H., Takeya K., et al. Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorg Med Chem 6 7 (1998) 1103-1115